{"schema_version":"secwatch.filing_event.v1","accession":"0001689548-25-000056","form_type":"8-K","ticker":"PRAX","cik":"0001689548","company_name":"Praxis Precision Medicines, Inc.","filed_at":"2025-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.345565+00:00","generated_at":"2026-05-22T22:53:49.591186+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Praxis posts Q1 net loss of $69.3M; cash $472M, runway into 2028","bullets":["Net loss $69.3M for Q1 2025 vs $39.6M YoY; R&D spend $60.8M (up 125% YoY).","Cash & investments $472M as of March 31, 2025; no revenue recognized.","Essential3 essential tremor trial continues after futility interim; topline Q3 2025.","Vormatrigine RADIANT topline mid-2025, POWER1 H2 2025; EMERALD & EMBRAVE3 studies to start mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001689548-25-000056","json":"https://secwatch.observer/filing/0001689548-25-000056.json","markdown":"https://secwatch.observer/filing/0001689548-25-000056.md","text":"https://secwatch.observer/filing/0001689548-25-000056.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689548/000168954825000056/0001689548-25-000056-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689548/000168954825000056/prax-20250502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T22:53:49.591186+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}